Atossa Therapeutics Inc
ATOS
Company Profile
Business description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Contact
1448 North West Market Street
Suite 500
SeattleWA98107
USAT: +1 206 588-0256
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 14.40 | -0.16% |
| CAC 40 | 8,157.91 | 15.99 | 0.20% |
| DAX 40 | 24,136.72 | 53.19 | 0.22% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,362.97 | 41.88 | 0.41% |
| HKSE | 25,679.78 | 245.87 | -0.95% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,764.40 | 110.54 | -0.86% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,710.70 | 10.50 | -0.12% |
| SSE Composite Index | 4,078.64 | 7.71 | -0.19% |